Trastuzumab Current Events

Trastuzumab Current Events, Trastuzumab News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 7 | 261 Results
Enhancing the effectiveness of a breast cancer treatment
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. Researchers have now identified a sequential treatment regimen that enhances the effectiveness of trastuzumab in xenotransplant models of breast cancer. (2012-02-13)

Powerful predictor of resistance may change management of therapy for breast cancer
Scientists have identified a new mechanism of action for the anticancer drug Herceptin (trastuzumab) that can be used to accurately predict whether or not a breast cancer patient will be resistant to treatment. The finding has dual significance, as it will allow patients who are unlikely to respond to trastuzumab to avoid unnecessary costs and side effects associated with treatment, and it provides new directions for designing strategies for overcoming treatment resistance. (2004-08-23)

Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug Trastuzumab (Herceptin) is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic review shows. However, the review, published in The Cochrane Library, concludes that more women benefit from use of Trastuzumab than are harmed. (2014-06-11)

Heart failure in older breast cancer patients linked to medication
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab, Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology. (2012-11-14)

Balancing trastuzumab's survival benefits and heart risks for women with breast cancer
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumors reappearing once therapy stops. At the same time, however, women given trastuzumab have a higher risk of experiencing problems with their heart. These findings are the key conclusions of a systematic review published in the Cochrane Library. (2012-04-17)

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab before and after surgery, according to results from the largest multi-center trial to investigate this treatment. The trial, presented at the 6th European Breast Cancer Conference in Berlin, showed that the women did not suffer any serious side-effects, such as heart problems, from the treatment. (2008-04-18)

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a (2008-03-10)

Single dose of trastuzumab kick starts immune response in certain breast cancers
A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published recently in Clinical Cancer Research. (2016-02-29)

Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?
EORTC trial 1203 -- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers. (2015-11-13)

Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab. (2009-09-14)

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab showed a statistically non-significant benefit in clinical response rates when everolimus is added to trastuzumab. (2013-05-02)

Romond heads up study and reduces breast cancer recurrence
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin®) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. Dr. Edward Romond, associate professor of medicine at the University of Kentucky College of Medicine and UK Markey Cancer Center, acts as principal investigator on the study and chairs the National Surgical Adjuvant Breast and Bowel Project (NSABP). (2005-04-26)

Study finds new triple drug combination increases tumour eradication in HER2-positive breast cancer by more than 50 percent compared with standard treatment
The addition of the monoclonal antibody pertuzumab to standard therapy for women with an aggressive type of early-stage breast cancer improved the rate of complete tumour disappearance by more than half after just four cycles of treatment compared with the standard regimen alone. (2011-12-06)

Genetic approach provides new insight into trastuzumab resistance in breast cancer
A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell, identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients. (2007-10-15)

Report in Circulation urges a closer look at cardiotoxicity of cancer drug trastuzumab (Herceptin)
According to a report by a University of Pittsburgh cardiologist published in the current edition of (2000-07-17)

Targeted therapy prolongs life in patients with HER2-positive breast cancer
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium. (2009-12-11)

Immune substances may help antibody-based drugs fight cancer
A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system. This new study is the first to indicate that the drug trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleukin 2 or 12. Both substances trigger the activity of immune cells known as natural killer cells. (2006-01-05)

Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients reports in the Annals of Oncology. (2004-01-12)

Researchers restore drug sensitivity in breast cancer tumors
A team of Case Western Reserve University School of Medicine cancer researchers has uncovered one way certain tumors resist vital medication. (2016-08-11)

Addition of trastuzumab may potentially equalize disease-free survival outcomes among obese and normal-weight patients
A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients. (2011-12-08)

Study finds it's safe to treat HER2-positive breast cancer with trastuzumab and adjuvant radiation
Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is trastuzumab (herceptin) -- typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both trastuzumab and adjuvant radiation therapy. (2009-11-03)

EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
Although the incidence of cancer is higher in persons over 65 years old, we still have an inadequate understanding on how best to treat elderly cancer patients. Elderly patients are occasionally included in clinical trials, but the included patients are mostly healthy, so the broader elderly patient population is not well represented. The EORTC Cancer in the Elderly Task Force has now opened a trial in for elderly patients with HER-2 positive metastatic breast cancer. (2013-06-19)

Trastuzumab raises risk of heart problems in the elderly with history of heart disease or diabetes
The first study to investigate the effect of the breast cancer drug trastuzumab (Herceptin) on heart and vascular function in elderly patients has found that it increases the risk of heart problems, particularly in women with a history of heart disease, diabetes or both. The research is published online in Annals of Oncology on Wednesday. (2011-08-09)

New breast cancer drug shrinks tumors or slows growth in up to half of women
A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans. (2004-06-06)

Study confirms long-lasting benefit of trastuzumab (herceptin) for women with early-stage breast cancer
Women with an aggressive type of early-stage breast cancer (HER2-positive disease) given trastuzumab (Herceptin) for one year following standard chemotherapy are at significantly less risk of the cancer returning, and the effect is long lasting, according to the long-term results of the landmark HERA trial published online first in The Lancet Oncology. (2011-02-24)

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial. (2010-12-10)

Mayo researchers to announce new findings about promising early-stage breast cancer treatment
During a poster discussion session at the 2005 American Society of Clinical Onscology (ASCO) Annual Meeting on Tuesday, May 17, Dr. Perez will discuss new information about the potential risk for heart muscle damage associated with the use of trastuzumab and chemotherapy. (2005-05-17)

Yale Cancer Center study validates combination therapy for aggressive endometrial cancer
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research. (2020-06-29)

Analysis confirms benefits of combining trastuzumab and chemotherapy
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer. (2007-07-07)

New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. (2012-10-01)

Headlines about Herceptin show equality of access to costly drugs must be tackled
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ. (2005-11-03)

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest. (2017-06-05)

Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib a novel small molecule inhibitor of the HER2 receptor appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy. (2009-05-28)

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (2018-05-16)

Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. An international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed. (2012-01-16)

Results good for HER-2 positive breast cancer patients using trastuzumab
Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug. Mayo Clinic's Michele Halyard, M.D., presented these findings today, June 5, at the 2006 American Society of Clinical Oncology (ASCO) annual meeting in Atlanta. (2006-06-05)

Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients
Early use of PI3K inhibitors may prevent or delay treatment resistance. Cancer cells resistant to anti-HER2 therapy had high levels of survivin. Newly identified biomarker may help predict anti-HER2 therapy resistance. (2013-01-23)

Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit
In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven. However, more patients discontinue treatment, particularly due to cardiac disorders. (2015-12-03)

Mayo researchers to announce new findings about promising early-stage breast cancer treatment
A study led by a Mayo Clinic medical oncologist and conducted by the North Central Cancer Treatment Group (NCCTG) provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and a drug called trastuzumab (Herceptin). (2005-05-16)

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (2014-09-28)

Page 1 of 7 | 261 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to